MUMBAI, India, Feb. 6 -- Intellectual Property India has published a patent application (202541123604 A) filed by Saveetha Institute Of Medical And Technical Sciences, Chennai, Tamil Nadu, on Dec. 8, 2025, for 'novel topical multipurpose cream formulation containing 0.1% tretinoin,1% luliconazole and 1% pramoxine hydrochloride for the management of dermatophytosis.'
Inventor(s) include Afrin Faheema J; Rajesh Kumar; and Deepak Nallaswamy Veeraiyan.
The application for the patent was published on Feb. 6, under issue no. 06/2026.
According to the abstract released by the Intellectual Property India: "Dermatophytosis, a superticial fungal infection affecting the skin, poses therapeutic challenges due to incomplete pathogen eradication, persistent inflammation, and pruritus, compounded by limited efticacy and poor penetration of conventional topical agents. Systemic therapies, while etlective, may carry risks of adverse effects and are inappropriate for long-tenn or mild infections. This study. presents a novel topical multipurpose cream fommlation containing 0.1% tretinoin, l% luliconazole, and I% pramoxine hydrochloride. Tretinoin accelerates epidermal turnover and enhances penetration of active ingredients, optimizing skin renewal and facilitating deeperreach-of-antifungal-therapy. the root cause of dennatophytosis, while pramoxine hydrochloride provides rapid relief of pruritus and improves patient comfort, supporting treatment adherence. The strategic combination of tretinoin, luliconazole, and pramoxine in a .flexible cream base enables sustained contact, maximizes local efficacy, and optimizes delivery, absorption, and symptomatic relief. This integrated approach delivers comprehensive, user-friendly advantages for patients with superficial fungal infections, supporting improved eradication, symptom control, and quality of life with minimized adverse effects and complexity compared to monotherapies or systemic regimens."
Disclaimer: Curated by HT Syndication.
